Venetoclax, a BCL2 inhibitor, in combination with hypomethylating agents has been shown to be efficacious in IDH-mutated AML, with an emphasis on IDH2-mutated AML [84, 85]. This evidence concerns the gene IDH2 and acute myeloid leukemia.